Under construction – not a live service
Sign in
Taking peopleNo phase

Radiation Free Study

Key facts

Where
Copenhagen, DenmarkSee the site

Where in Denmark

  • Rigshospitalet University HospitalCopenhagen, DenmarkContact: Timothy Resch (principal investigator)Not yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Philips Clinical & Medical Affairs Global
Trial code
NCT06549348
Record updated
15 June 2026
Original description
This is a prospective, randomized, unblinded, multi-center study. Sites were selected from different geographies (EU and US) with different clinical practice to ensure the results are more generalizable.Read full original descriptionShow less

This is a prospective, randomized, unblinded, multi-center study. Sites were selected from different geographies (EU and US) with different clinical practice to ensure the results are more generalizable.

Primary objective is to demonstrate that the average procedure fluoroscopy time using LumiGuide is lower compared to conventional fluoroscopy guidance in Fenestrated Endovascular Aortic Repair (FEVAR)

Inclusion: Subject will be undergoing a primary Fenestrated Endovascular Aortic Repair (FEVAR) procedure (including subjects with prior infrarenal EVAR or open repair) that includes the incorporation of visceral arteries into the repair; Subject is able to give informed consent and is 18 years of age or older, or of legal age to give informed consent per state or national law; Subject has a life expectancy of at least 2 years; Target vessels to be included are the Celiac Trunk, Superior Mesenteric Artery and Renal Arteries.

Exclusion: Subject participates in a potentially confounding drug or device trial during the course of the study. Co-enrollment in concurrent trials may be allowed provided that pre-approval is obtained from Philips; Subject with connective tissue disorder eg, Marfan's or Ehlers Danlos Syndrome; Subject with contrast allergies; Subjects undergoing an endovascular procedure that include branches or iliac branched devices (IBD) in the repair; Subject treated for re-intervention / staged procedure post-primary FEVAR procedure; Subjects intended to be treated for more than 4 target vessels (not counting the contralateral gate); Subject treated for an emergent (<24hrs after emergence) procedure; All vulnerable subjects such as immuno-compromised subjects, subjects lacking the capacity to provide consent, patients in emergency situations, pregnant or breast-feeding women, or any other subject who meets an exclusion criteria, according to applicable national laws, if any; Subject unwilling or unable to comply with the protocol unable to understand verbal and/or written informed consent.

ClinicalTrials.gov NCT06549348